Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03816293 · ClinicalTrials.gov registry record · NA
SUpPress SSI - Single Use Negative Pressure Wound Therapy (NPWT) to Reduce Surgical Site Infections
A NA study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- NA
- Development phase
- 3,680
- Enrollment target
NCT03816293: Completed NA study, sponsored by University of Illinois at Chicago.
NCT03816293 is a NA study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 3,680 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03816293, a NA study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,680 participants
- Enrollment target
Study Summary
Our goal is to provide data that will give surgeons and hospitals clear recommendations on the use of NPWT for Cesarean section, abdominal hysterectomy and colon surgeries in patients with diabetes and/or obesity. We also want to understand the patient experience with the dressing so that we can provide information that will enable clinicians to remove barriers to NPWT use. Additionally, we are seeking to use automated electronic medical record decision support to identify patients that will benefit most from the NPWT.
Primary Outcome
Superficial , Deep and organ space infections after surgery
Interventions
- DEVICE Negative Pressure Wound Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,680 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-09-30 |
| Phase | NA |
What the finished NCT03816293 record still lists
NCT03816293 is an interventional study that assigns participants to a tested intervention. Its 3,680 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 1 intervention - of which Negative Pressure Wound Therapy is the first listed.
NCT03816293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03816293 about?
NCT03816293 is a clinical study titled "SUpPress SSI - Single Use Negative Pressure Wound Therapy (NPWT) to Reduce Surgical Site Infections". Our goal is to provide data that will give surgeons and hospitals clear recommendations on the use of NPWT for Cesarean section, abdominal hysterectomy and colon surgeries in patients with diabetes and/or obesity. We also want to understand the patient experience with the dressing so that we can pro...
What is the current status of trial NCT03816293?
This trial is currently completed. It is a NA study. The enrollment target is 3,680 participants. The study started on 2019-05-01. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT03816293?
The interventions under investigation include: Negative Pressure Wound Therapy (DEVICE).
Who is sponsoring clinical trial NCT03816293?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03816293's enrollment target sits among peer trials
3,680 36th of 2000 higher than 1,965 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI